IS5183A - A method of enhancing the antineoplastic activity of unprocessed drugs, a mixture that enhances the anti-neoplastic activity of an unprocessed drug, a method of assessing the anti-neoplastic efficacy of the treatment of an unfinished drug, and a method of assessing the anti-tumor efficacy of an unfinished drug. - Google Patents

A method of enhancing the antineoplastic activity of unprocessed drugs, a mixture that enhances the anti-neoplastic activity of an unprocessed drug, a method of assessing the anti-neoplastic efficacy of the treatment of an unfinished drug, and a method of assessing the anti-tumor efficacy of an unfinished drug.

Info

Publication number
IS5183A
IS5183A IS5183A IS5183A IS5183A IS 5183 A IS5183 A IS 5183A IS 5183 A IS5183 A IS 5183A IS 5183 A IS5183 A IS 5183A IS 5183 A IS5183 A IS 5183A
Authority
IS
Iceland
Prior art keywords
drug
unfinished
assessing
unprocessed
neoplastic
Prior art date
Application number
IS5183A
Other languages
Icelandic (is)
Inventor
Niwa Kozo
Original Assignee
Niwa Kozo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Niwa Kozo filed Critical Niwa Kozo
Publication of IS5183A publication Critical patent/IS5183A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/071—Agaricus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS5183A 1998-09-17 1999-09-17 A method of enhancing the antineoplastic activity of unprocessed drugs, a mixture that enhances the anti-neoplastic activity of an unprocessed drug, a method of assessing the anti-neoplastic efficacy of the treatment of an unfinished drug, and a method of assessing the anti-tumor efficacy of an unfinished drug. IS5183A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26375398 1998-09-17
JP10323374A JP2000159682A (en) 1998-09-17 1998-11-13 Crude drug antitumor activity enhancing method, antitumor activity enhancing crude drug-containing composition, antitumor efficacy evaluating method of crude drug treatment, and antitumor efficacy evaluating method of crude drug

Publications (1)

Publication Number Publication Date
IS5183A true IS5183A (en) 2000-03-17

Family

ID=26546176

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5183A IS5183A (en) 1998-09-17 1999-09-17 A method of enhancing the antineoplastic activity of unprocessed drugs, a mixture that enhances the anti-neoplastic activity of an unprocessed drug, a method of assessing the anti-neoplastic efficacy of the treatment of an unfinished drug, and a method of assessing the anti-tumor efficacy of an unfinished drug.

Country Status (19)

Country Link
JP (1) JP2000159682A (en)
KR (1) KR20000023206A (en)
CN (1) CN1255376A (en)
AU (1) AU4486299A (en)
BE (1) BE1012725A5 (en)
CA (1) CA2282234A1 (en)
DE (1) DE19944695A1 (en)
DK (1) DK199901235A (en)
ES (1) ES2155802B1 (en)
FR (2) FR2783426A1 (en)
GB (2) GB9920710D0 (en)
ID (1) ID23150A (en)
IL (1) IL131722A0 (en)
IS (1) IS5183A (en)
IT (1) IT1307267B1 (en)
NL (2) NL1013049C2 (en)
NO (1) NO994463L (en)
SE (2) SE9903307L (en)
SG (1) SG76631A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60218299T2 (en) * 2001-04-27 2007-10-31 Ajinomoto Co., Inc. A dispersion of beta-glucan-containing superfine particles, a corresponding manufacturing process and the use of the dispersion
EP1385970A4 (en) * 2001-05-07 2004-11-24 Biohub Co Ltd PROCESS FOR THE PREPARATION OF LACTIC FERMENTATION SOLUTION BASED ON FUNGUS AND SOLUTION THUS OBTAINED
JP4499979B2 (en) * 2001-05-21 2010-07-14 コンビ株式会社 Composition for controlling pathogen infection
JP4561098B2 (en) * 2001-06-01 2010-10-13 味の素株式会社 Diabetes medicine
TWI330533B (en) 2002-05-15 2010-09-21 Bhn Co Ltd Composition for angiogenesis inhibition, neoplasm inhibition,or immunostimulation
JP4681801B2 (en) * 2002-05-15 2011-05-11 ビーエイチエヌ株式会社 Angiogenesis inhibitor and method for producing the same
JP4826696B2 (en) * 2003-04-07 2011-11-30 ビーエイチエヌ株式会社 Angiogenesis inhibitors
JP2005089417A (en) * 2003-09-19 2005-04-07 Noevir Co Ltd Composition for prevention/treatment of diabetes
JP4587441B2 (en) * 2004-02-12 2010-11-24 株式会社クレハ Novel diabetes treatment and food
WO2006030750A1 (en) 2004-09-17 2006-03-23 Ssi Co., Ltd. Extract from agaricus blazei murrill capable of inhibiting breast cancer
JP2006273835A (en) * 2005-03-04 2006-10-12 Michishi Tani Malignant tumor therapeutic agent and food and drink containing the same
WO2011014729A1 (en) * 2009-07-31 2011-02-03 Yukiguni Maitake Co., Ltd. Maitake mushroom coffee
JPWO2011081024A1 (en) * 2009-12-29 2013-05-09 株式会社富士見養蜂園 Umami food and production method thereof
CN106309511A (en) * 2016-08-30 2017-01-11 青海民族大学 Effective part of agaricus gennadii for inhibiting CDC25 enzyme as well as preparation method and application of effective part
CN106333969A (en) * 2016-08-30 2017-01-18 青海民族大学 Agaricus gennadii HDAC1 enzyme inhibition effective part and preparation method and application
US20200397817A1 (en) * 2017-11-30 2020-12-24 SHIEH, Darbin Method for predicting and modulating susceptibility of cancer cell to programmed cell death
KR102646421B1 (en) * 2020-12-16 2024-03-12 대한민국 Method for increasing the content of physiologically active ingredients and nutrients in Grifola frondosa
KR102602787B1 (en) * 2020-12-16 2023-11-17 대한민국 Method for increasing the content of physiologically active ingredients and nutrients in Sparassis crispa
KR102584680B1 (en) * 2020-12-17 2023-10-06 대한민국 Method for manufacturing tea of Lentinula edodes tea improved physiological activities and nutrition components

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276413A (en) * 1975-12-18 1977-06-27 Kureha Chem Ind Co Ltd Production of oncostatic substances
US4177108A (en) * 1977-03-02 1979-12-04 Tetsuro Ikekawa Process for producing emitanin
DE2842691A1 (en) * 1978-09-30 1980-04-10 Karl Dr Med Theurer Activation of pharmaceuticals by irradiation - using wavelengths corresp. to absorption maxima of the substance, opt. with the simultaneous application of magnetic field
JPS57206618A (en) * 1981-06-12 1982-12-18 Noda Shiyokukin Kogyo Kk Preparation of antitumor substance
JPH02203765A (en) * 1989-02-02 1990-08-13 Nippon Beet Sugar Mfg Co Ltd Food having antitumor function and production thereof
JP3357383B2 (en) * 1991-08-14 2002-12-16 昌宏 黒田 Low molecular weight plant composition
JP2955126B2 (en) * 1992-06-22 1999-10-04 笑代 丹羽 Pharmaceutical oleaginous preparation, food oleaginous preparation and production method thereof
US6015913A (en) * 1996-09-06 2000-01-18 Mars, Incorporated Method for producing fat and/or solids from cocoa beans

Also Published As

Publication number Publication date
ITTO990784A1 (en) 2001-03-14
DE19944695A1 (en) 2000-03-30
NL1013049C2 (en) 2002-01-11
BE1012725A5 (en) 2001-02-06
SE0100195D0 (en) 2001-01-24
CA2282234A1 (en) 2000-03-17
ITTO990784A0 (en) 1999-09-14
KR20000023206A (en) 2000-04-25
GB9921387D0 (en) 1999-11-10
GB9920710D0 (en) 1999-11-03
GB2341800A (en) 2000-03-29
ES2155802A1 (en) 2001-05-16
SE9903307D0 (en) 1999-09-16
FR2783426A1 (en) 2000-03-24
NL1013049A1 (en) 2000-03-21
IT1307267B1 (en) 2001-10-30
NL1019705C2 (en) 2002-03-26
FR2788697A1 (en) 2000-07-28
JP2000159682A (en) 2000-06-13
DK199901235A (en) 2000-03-18
SG76631A1 (en) 2000-11-21
SE9903307L (en) 2000-03-18
ID23150A (en) 2000-03-23
SE0100195L (en) 2001-01-24
NO994463D0 (en) 1999-09-15
NL1019705A1 (en) 2002-01-29
ES2155802B1 (en) 2001-12-01
NO994463L (en) 2000-03-20
AU4486299A (en) 2000-03-30
CN1255376A (en) 2000-06-07
IL131722A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
IS5183A (en) A method of enhancing the antineoplastic activity of unprocessed drugs, a mixture that enhances the anti-neoplastic activity of an unprocessed drug, a method of assessing the anti-neoplastic efficacy of the treatment of an unfinished drug, and a method of assessing the anti-tumor efficacy of an unfinished drug.
WO2003090695A3 (en) TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
NO20004654D0 (en) Gastroprotected omeprazole microgranules, method for obtaining such and pharmaceutical preparations
EP1363625A4 (en) Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
PL362690A1 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
ZA200407813B (en) Medicament for preventing and/or treating chronic rejection.
ZA200208492B (en) Game server, game machine under control of the server, and game control method.
ZA200206612B (en) Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction.
NO20033440L (en) Treatment of neurological dysfunction including fructopyranose sulfamates and erythropoietin
DK1066056T4 (en) Iron dextran compound for use as a component of a therapeutic agent for the prevention or treatment of iron deficiency, method of preparing the iron dextran compound and use of this compound for the manufacture of an ...
IS6202A (en) Pharmaceutical recipes and methods for administering morphine noses
ZA200108012B (en) Method of enhancing the efficacy of anti-tumor agents.
MXPA03003632A (en) METHOD FOR TUMOR TREATMENT USING COMBINATION THERAPY.
CY2367B1 (en) Swallow tablet comprising paracetamol.
MXPA03008582A (en) Agents and methods for treatment of cancer.
ZA200309733B (en) Method and apparatus for distributing treatment agents.
TR199801871A3 (en) Biphenylsulfonylcyanamides production method and their use as drugs.
RU2003102402A (en) METHOD FOR FORMING BILATERAL ENCLOSURE Pancreatoenteroanastomosis After Medial Pancreatic Resection
IS5809A (en) Concomitant administration of ACAT and MMP inhibitors for the treatment of fat degeneration
NL1017117A1 (en) A method of enhancing the anti-tumor activity of an amygdaline-containing material, a composition containing an enhanced amygdaline-containing material, a method of evaluating the anti-tumor effectiveness of a treatment of amygdaline-containing material, and a method of evaluating amygdaline-containing anti-tumor material.
MXPA03003032A (en) Combination therapy for the treatment of estrogen-sensitive disease.
MXPA03006157A (en) Hormone replacement therapy method and its administration form.
RU2001129920A (en) The method of phage therapy of tuberculosis
ITRM20020308A1 (en) THERAPEUTIC TREATMENT EQUIPMENT, AND RELATED METHOD.
ZA200402285B (en) Ophthalmologic treatment methods using selective iNOS inhibitors.